FIELD: pharmaceuticals.
SUBSTANCE: invention relates to pharmaceutical chemistry and pharmacology and can be used to create new medicinal products for preventing thrombosis and thromboembolic complications. Disclosed is an application of calcium L-aspartate tetrahydrate by the formula as an agent exhibiting antiaggregatory activity.
EFFECT: production of an agent with antiaggregatory activity.
1 cl, 2 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
TRIAZOLE DERIVATIVES EXHIBITING ANTIAGGREGATORY ACTIVITY | 2021 |
|
RU2770405C1 |
AGENT EXHIBITING ANTIAGGREGATORY ACTIVITY | 2019 |
|
RU2727508C1 |
DERIVATIVES OF 1-(3,5-DI-TERT-BUTYL-4-HYDROXYBENZYL)ISATIN HAVING ANTIAGGREGATORY ACTIVITY | 2023 |
|
RU2822271C1 |
USE OF 4-O-α-ARABINOFURANOSYLAGIC ACID AS ANTI-AGGREGATION ACTIVITY | 2023 |
|
RU2811240C1 |
USE OF 5,7-DIHYDROXY-6,8-DIMETHYLFLAVANONE AS ANTI-AGGREGATION ACTIVITY | 2023 |
|
RU2812630C1 |
AGENT SHOWING ANTIAGGREGANT AND ANTITHROMBOGENIC ACTIVITY | 2010 |
|
RU2453312C1 |
USE OF 2,3,4-TRIMETHOXY-5-HYDROXY-9,10-DIHYDROPHENANTHRENE AS AN AGENT WITH ANTI-AGGREGATION ACTIVITY | 2023 |
|
RU2808460C1 |
NITROESTER OF OXIDIZED STARCH SODIUM SALT SHOWING ANTIAGGREGANT ACTION | 1991 |
|
RU2074195C1 |
2-(1S,2R,5S)-6,6-DIMETHYLBICYCLO[3.1.1]HEPT-2YL]METHYL}THIONYL)ETHANOIC ACID, HAVING ANTIAGGREGANT ACTION | 2013 |
|
RU2522198C2 |
USE OF 1-(3,5-DIHYDROXY-4-METHOXYPHENYL)-2-(3-HYDROXYPHENYL)-ETHANE WITH ANTI-AGGREGATION ACTIVITY | 2023 |
|
RU2806331C1 |
Authors
Dates
2022-08-23—Published
2021-08-12—Filed